Activity Summary:
To reinforce key insights and facilitate post-activity implementation, participants can download, on-demand resources designed to support ongoing clinical decision-making. These concise, easy-to-reference tools translate emerging evidence into practical strategies that clinicians can reference when integrating today’s most effective therapeutic approaches.

Clinical Slide Deck:
A curated set of high-yield, evidence-based slides including data visuals, algorithms, and expert insights.

Expert Commentary Transcripts:
A downloadable transcript of the podcast/video for learners who prefer a text-based review.

Strengthen your knowledge. Support your practice. Improve patient care.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:

CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.

In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.

Activity Summary:

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.

Activity Summary:
To further expand knowledge from the What's New Doc? End-of-the-Year Updates on IPF presented by Dr. Steven Nathan, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights
Concise, one-page summaries of key IPF studies featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
These clinical videos and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at the annual hematology meeting December 6-9 in Orlando, FL. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights covers leukemia, myelodysplastic syndromes (MDS), myelofibrosis (MF), as well as hemophilia A and B. Please click the links to participate in each of these activities.

Activity Summary:
A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Enhance your learning from the Hematologic Cancer Updates activity with a curated resource library built for real-world clinical needs. Access downloadable visual summaries, practical takeaways and ready-to-share content—ideal for quick reference and team-based discussions, and perfectly aligned with the podcast and highlights video.

Clinical Slide Deck: Downloadable PDF of presentation slides, including data visuals, algorithms and expert insights—ideal for review, teaching or clinical discussions.

Clinical Snippet Highlights: Concise, one-page summaries of key posters and abstracts, offering quick, actionable insights to support day-to-day clinical decision-making.

Expert Commentary Transcript: A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Despite advances in understanding PAH, several opportunities remain to further improve patient outcomes, particularly in timely diagnosis, the differentiation to other PH subtypes, treatment challenges, and the management of cardiovascular comorbidities.

During these two Clinical Snippet episodes, Dr. Oudiz highlights the latest advances in PAH that were presented at fall conferences in Seattle, WA; Chicago, IL; and Amsterdam, Netherlands in September-October 2025.

Activity Summary:

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Activity Summary:
PH is currently divided into groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This educational slide kit presents the latest research in diagnosing and managing Group 2-5 in patients, including the distinction of specific groups – CTEPH, PH-ILD, PH-COPD, CPFE, CTD.

Activity Summary:
Novel therapies and combinations are currently under investigation for the treatment of acute myeloid leukemia (AML). These include venetoclax, FLT3 inhibitors, IDH inhibitors, menin inhibitors, antibody-drug conjugates, CAR T-cell approaches, and novel targeted agents. Similarly, a number of clinical trials are underway for other leukemias, myelodysplastic syndromes (MDS) and myelofibrosis (MF).

In this Conference Highlights accredited video, Dr. Raajit Rampal discusses the latest cutting-edge evidence in leukemia, MDS and MF, presented in Orlando, FL December 6th – 9th, integrating new evidence into personalized approaches, optimizing patient outcomes and improving the overall quality of care.

Activity Summary:
New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated care, and earlier intervention to improve daily functioning and long-term outcomes.

This CME activity brings all these findings together in one clear, concise program that helps clinicians keep pace with a rapidly changing field and deliver more effective, patient-focused care.

Activity Summary:
IPF care is shifting fast, and this year brought major data that will influence how clinicians diagnose, monitor, and manage disease in the year ahead. What’s New Doc? End-Of-The-Year Updates on IPF is a focused, high-impact CME activity designed to give pulmonologists, ILD specialists, and multidisciplinary care teams a clear view of the most important 2025 findings and how they translate to practice.

This activity reviews new epidemiologic insights, real-world antifibrotic outcomes, patient-reported challenges, and the latest trial results for emerging therapies expected to shape care in 2026. Steven Nathan, MD guides learners through the evidence with practical takeaways that support better decision making on diagnosis, therapy selection, tolerability management, and quality-of-life improvement.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.